Clinical Trial: Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma

U.S., Jan. 21 -- ClinicalTrials.gov registry received information related to the study (NCT03568461) titled 'Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma' on May 24, 2018.

Brief Summary: This is a multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory FL.

Study Type: Interventional

Condition: Follicular Lymphoma

Intervention: Biological: tisagenlecleucel

single infusion

Recruitment Status: Recruiting

Sponsor: Novartis Pharmaceuticals

Information provided by (Responsible Party): Novartis ( Novartis Pharmaceuticals )

Published by HT Digital Content Services with permission from Health Daily Digest....